US5527527A
(en)
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5154924A
(en)
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5260210A
(en)
|
1989-09-27 |
1993-11-09 |
Rubin Lee L |
Blood-brain barrier model
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
US5254342A
(en)
|
1991-09-30 |
1993-10-19 |
University Of Southern California |
Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
|
FR2705194A1
(fr)
|
1993-05-21 |
1994-11-25 |
Transgene Sa |
Animal transgénique exprimant une transferrine d'origine humaine.
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
AU8269898A
(en)
|
1997-06-27 |
1999-01-19 |
Regents Of The University Of California, The |
Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
|
JP2003512019A
(ja)
|
1999-01-15 |
2003-04-02 |
ジェネンテック・インコーポレーテッド |
変化したエフェクター機能を有するポリペプチド変異体
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7241449B1
(en)
|
1999-04-12 |
2007-07-10 |
Aventis Pasteur Limited |
Transferrin receptor genes of moraxella
|
CA2382812A1
(en)
|
1999-08-30 |
2001-03-08 |
Joseph Schlessinger |
Crystal structures of domains of receptor protein tyrosine kinases and their ligands
|
CA2400802A1
(en)
|
2000-02-08 |
2001-08-16 |
University Of British Columbia |
Compositions and methods for screening therapeutic agents
|
JP2001238681A
(ja)
|
2000-03-03 |
2001-09-04 |
Japan Science & Technology Corp |
共培養による血液脳関門再構築モデル
|
AU2002236499A8
(en)
|
2000-11-30 |
2009-12-03 |
Uab Research Foundation |
Receptor-mediated uptake of peptides that bind the human transferrin receptor
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン,エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
AU2002315398A1
(en)
|
2001-06-29 |
2003-03-03 |
Wyeth |
Methods and compositions useful for the prediction of blood-brain barrier permeation
|
US20030226155A1
(en)
|
2001-08-30 |
2003-12-04 |
Biorexis Pharmaceutical Corporation |
Modified transferrin-antibody fusion proteins
|
BRPI0213207B1
(pt)
|
2001-10-10 |
2021-06-15 |
Novo Nordisk A/S |
Processo in vitro, isento de células, para a remodelagem de um peptídeo e processos para formar um conjugado entre peptídeos e um grupo de modificação
|
US20030074141A1
(en)
|
2001-10-15 |
2003-04-17 |
Camitro Corporation |
Meta-models for predicting blood brain barrier penetration based on simple physicochemical descriptors
|
CN1713920A
(zh)
*
|
2002-08-30 |
2005-12-28 |
比奥雷克西斯药物公司 |
被修饰的转铁蛋白融合蛋白
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP1620564A4
(en)
|
2003-04-18 |
2008-03-12 |
Cytovia Inc |
METHOD FOR TREATING DISEASES RESPONSING TO APOPTOSIS INDUCTION AND SCREENING TESTS
|
US20050249723A1
(en)
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
US20050170394A1
(en)
|
2004-01-30 |
2005-08-04 |
Xenoport, Inc. |
GLUT1 transporters expressed in blood brain barrier cells
|
GB0403490D0
(en)
|
2004-02-17 |
2004-03-24 |
Daniolabs Ltd |
Screening methods
|
FR2871162B1
(fr)
|
2004-06-02 |
2007-06-29 |
Univ Paris 7 Denis Diderot |
Materiau de surface modifiee, son procede de preparation et ses utilisations
|
CN102746404B
(zh)
|
2004-11-12 |
2016-01-20 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
EP1817410B1
(en)
|
2004-11-29 |
2015-01-07 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Human blood brain barrier model
|
PL1772465T3
(pl)
|
2005-01-05 |
2009-08-31 |
F Star Biotechnologische Forschungs Und Entw M B H |
Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność
|
US8900865B2
(en)
|
2005-12-14 |
2014-12-02 |
The Invention Science Fund I, Llc |
Blood brain barrier device
|
JP5113332B2
(ja)
|
2005-12-19 |
2013-01-09 |
正美 丹羽 |
血液脳関門インヴィトロ・モデル、病態血液脳関門インヴィトロ・モデル、及びこれを用いた薬物スクリーニング方法、病態血液脳関門機能解析方法、病因解析方法
|
WO2007143711A2
(en)
|
2006-06-07 |
2007-12-13 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
US20080044847A1
(en)
|
2006-06-23 |
2008-02-21 |
Shusta Eric V |
Blood-Brain Barrier Model
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
AU2007280398B2
(en)
|
2006-08-01 |
2012-05-10 |
Pieris Ag |
Muteins of tear lipocalin and methods for obtaining the same
|
CA2661042C
(en)
|
2006-08-18 |
2012-12-11 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
US8921279B2
(en)
|
2007-06-26 |
2014-12-30 |
F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H |
Display of binding agents
|
CA2693742A1
(en)
|
2007-07-12 |
2009-01-15 |
Prosensa Technologies B.V. |
Molecules for targeting compounds to various selected organs, tissues or tumor cells
|
CA3052615A1
(en)
|
2008-01-31 |
2009-08-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Engineered antibody constant domain molecules
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
AU2009256246B2
(en)
|
2008-06-03 |
2013-07-18 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2010014622A2
(en)
|
2008-07-28 |
2010-02-04 |
Fondazione Istituto Firc Di Oncologica Molecolare (Ifom) |
In vitro model for modulating the blood brain barrier and methods of screening
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
JP5781501B2
(ja)
|
2009-04-22 |
2015-09-24 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
改変されたFcRn結合部位を有する抗体融合タンパク質
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
US8417465B2
(en)
|
2009-11-04 |
2013-04-09 |
Cfd Research Corporation |
Synthetic microfluidic blood-brain barrier
|
WO2011100058A1
(en)
|
2010-02-09 |
2011-08-18 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
AU2011244282A1
(en)
|
2010-04-20 |
2012-11-15 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
KR20130092589A
(ko)
|
2010-10-29 |
2013-08-20 |
에프. 호프만-라 로슈 아게 |
Il33 n―말단 도메인 결실을 갖는 염증의 쥣과 모델
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
TW201305200A
(zh)
|
2010-11-30 |
2013-02-01 |
Genentech Inc |
低親和力血腦障壁受體抗體及其用途
|
EP2682401A4
(en)
|
2011-02-02 |
2015-06-03 |
Microbial Chem Res Found |
FOR OBTAINING THE BLOOD-BRAIN-DISABLED MEDICAMENT OUTPUT MATERIAL, PEPTIDE THEREOF AND USE THEREOF
|
MX348071B
(es)
|
2011-03-16 |
2017-05-26 |
Amgen Inc |
Variantes de fc.
|
AU2012244816B2
(en)
|
2011-04-20 |
2015-12-10 |
Roche Glycart Ag |
Method and constructs for the pH dependent passage of the blood-brain-barrier
|
CA2832387A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
EA201892619A1
(ru)
*
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
CN109517059B
(zh)
|
2011-06-30 |
2023-03-28 |
中外制药株式会社 |
异源二聚化多肽
|
EP2546268A1
(en)
|
2011-07-13 |
2013-01-16 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Internalising immunoglobulin
|
EP2568051A1
(en)
|
2011-09-07 |
2013-03-13 |
Stallergenes S.A. |
Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy
|
DK177327B1
(en)
|
2011-12-23 |
2013-01-14 |
Entomopharm Aps |
OPTIMIZED INSECT BASED EX VIVO MODEL FOR EXAMINATION OF BLOOD BRAIN BARRIER penetration and method of exposing the insect brain to chemical compounds
|
WO2013118858A1
(ja)
|
2012-02-09 |
2013-08-15 |
中外製薬株式会社 |
抗体のFc領域改変体
|
US9475840B2
(en)
|
2012-02-27 |
2016-10-25 |
Universitat De Barcelona |
Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
|
JP6883944B2
(ja)
|
2012-03-14 |
2021-06-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多重特異性抗原結合分子およびその使用
|
US9676857B2
(en)
|
2012-03-16 |
2017-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Soluble engineered monomeric Fc
|
KR102177252B1
(ko)
|
2012-04-23 |
2020-11-10 |
가부시키가이샤 에스 앤드 케이 바이오파마 |
락토페린 융합 단백질 및 그의 제조방법
|
AU2013266611B2
(en)
|
2012-05-21 |
2016-08-11 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
EP2855520B1
(en)
|
2012-06-04 |
2018-09-26 |
Novartis AG |
Site-specific labeling methods and molecules produced thereby
|
WO2013187495A1
(ja)
|
2012-06-14 |
2013-12-19 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
US9513280B2
(en)
|
2012-08-28 |
2016-12-06 |
University Of Utah Research Foundation |
Microfluidic biological barrier model and associated method
|
EP2890712B1
(en)
|
2012-08-29 |
2019-05-01 |
F.Hoffmann-La Roche Ag |
Blood brain barrier shuttle
|
US10590393B2
(en)
|
2012-11-08 |
2020-03-17 |
Wisconsin Alumni Research Foundation |
Retinoic acid enhanced human stem cell derived blood brain barrier model
|
US9932559B2
(en)
|
2012-11-16 |
2018-04-03 |
The Johns Hopkins University |
Platform for creating an artificial blood brain barrier
|
WO2014089209A2
(en)
|
2012-12-04 |
2014-06-12 |
Abbvie, Inc. |
Blood-brain barrier (bbb) penetrating dual specific binding proteins
|
CN105102618B
(zh)
|
2012-12-27 |
2018-04-17 |
中外制药株式会社 |
异源二聚化多肽
|
WO2014144060A1
(en)
|
2013-03-15 |
2014-09-18 |
Alper Biotech, Llc |
Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
PT2978840T
(pt)
|
2013-03-26 |
2021-01-06 |
Univ Of Artois |
Um modelo de barreira hematoencefálica humana derivado de células estaminais
|
TWI523945B
(zh)
|
2013-03-29 |
2016-03-01 |
Nat Univ Chung Cheng |
Establishment of blood - brain barrier model in
|
RU2019108429A
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
|
CA2911344C
(en)
|
2013-05-14 |
2022-08-30 |
California Institute Of Technology |
Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
BR112015029788B1
(pt)
|
2013-05-31 |
2024-01-02 |
Zymeworks Inc |
HETERO-MULTÍMERO, USO E MÉTODO PARA PREPARAR DO MESMO, COMPOSIÇÃO FARMACÊUTICA E MÉTODO PARA REDUZIR FUNÇÃO EFETORA DE UM CONSTRUTO IgG FC
|
AU2014298519A1
(en)
|
2013-08-02 |
2016-02-04 |
F. Hoffmann-La Roche Ag |
Therapeutic fusion protein
|
ES2928155T3
(es)
|
2013-08-19 |
2022-11-15 |
S M Discovery Holdings Inc |
Composición de nanoadministración peptídica que se dirige a dos receptores
|
US11261262B2
(en)
|
2013-09-03 |
2022-03-01 |
Novimmune Sa |
Readily isolated bispecific binding molecules with native format having mutated constant regions
|
SG10202007189VA
(en)
|
2013-11-21 |
2020-09-29 |
Hoffmann La Roche |
ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
|
EP3088518A4
(en)
|
2013-12-25 |
2017-09-20 |
JCR Pharmaceuticals Co., Ltd. |
Novel anti-transferrin receptor antibody that passes through blood-brain barrier
|
EP3089996B1
(en)
|
2014-01-03 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
CN111057151B
(zh)
|
2014-01-06 |
2022-05-03 |
豪夫迈·罗氏有限公司 |
单价血脑屏障穿梭模块
|
US9629801B2
(en)
|
2014-01-10 |
2017-04-25 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
BR112016016274A2
(pt)
|
2014-02-19 |
2017-10-03 |
Hoffmann La Roche |
Ponte da barreira hematoencefálica
|
US20160002343A1
(en)
|
2014-06-11 |
2016-01-07 |
Abbvie Inc. |
Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
EP2995949A1
(en)
|
2014-09-09 |
2016-03-16 |
Institut Pasteur |
New in vitro blood brain barrier model
|
AU2015346045B2
(en)
|
2014-11-14 |
2021-08-26 |
Ossianix, Inc. |
Variable new antigen receptors (VNARs) directed against transferrin receptor (TfR) and their use
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法
|
MX2017006626A
(es)
|
2014-11-20 |
2017-08-21 |
Hoffmann La Roche |
Cadenas ligeras comunes y metodos de uso.
|
CA2970173A1
(en)
|
2014-12-09 |
2016-06-16 |
National Research Council Of Canada |
Human blood brain barrier model
|
WO2016202343A1
(en)
|
2015-06-19 |
2016-12-22 |
Aalborg Universitet |
A triple co-culture model of the blood-brain barrier using primary porcine brain endothelial cells, porcine pericytes and porcine astrocytes
|
CA2990785A1
(en)
*
|
2015-06-24 |
2016-12-29 |
Jcr Pharmaceuticals Co., Ltd. |
Anti-human transferrin receptor antibody permeating blood-brain barrier
|
IL302486A
(en)
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
JP7021955B2
(ja)
|
2015-06-24 |
2022-03-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Her2及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
|
CA2990565A1
(en)
|
2015-06-24 |
2016-12-29 |
Jcr Pharmaceuticals Co., Ltd. |
Fusion protein containing bdnf and anti-human transferrin receptor antibody
|
CA2987641A1
(en)
|
2015-07-06 |
2017-01-12 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules and uses thereof
|
WO2017035119A1
(en)
|
2015-08-24 |
2017-03-02 |
National University Of Singapore |
Blood brain barrier model in a 3d co-culture microfluidic system
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
TWI747843B
(zh)
|
2015-10-02 |
2021-12-01 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
US10233252B2
(en)
|
2015-12-21 |
2019-03-19 |
Wisconsin Alumni Research Foundation |
pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
|
EP3411406A1
(en)
|
2016-02-05 |
2018-12-12 |
Genmab A/S |
Multispecific antigen-binding molecule with improved internalization characteristics
|
AR108377A1
(es)
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
US20200317749A1
(en)
|
2016-07-01 |
2020-10-08 |
Denali Therapeutics Inc. |
Albumin variants for enhanced serum half-life
|
US11498974B2
(en)
|
2016-07-14 |
2022-11-15 |
Bioarctic Ab |
Brain delivery protein
|
CA3033082A1
(en)
|
2016-08-06 |
2018-02-15 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
WO2018117613A1
(ko)
|
2016-12-19 |
2018-06-28 |
한미약품 주식회사 |
뇌 표적 지속성 단백질 결합체
|
JP7072524B2
(ja)
|
2016-12-26 |
2022-05-20 |
Jcrファーマ株式会社 |
Bdnfを含む融合蛋白質
|
TWI761413B
(zh)
|
2016-12-26 |
2022-04-21 |
日商Jcr製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
US10457717B2
(en)
|
2017-02-17 |
2019-10-29 |
Denali Therapeutics Inc. |
Engineered polypeptides
|
US10143187B2
(en)
|
2017-02-17 |
2018-12-04 |
Denali Therapeutics Inc. |
Transferrin receptor transgenic models
|
IL268660B2
(en)
|
2017-02-17 |
2024-03-01 |
Denali Therapeutics Inc |
Polypeptides that bind to a transgenic transferrin receptor, polynucleotides encoding them, methods for their preparation and use
|
MA47499A
(fr)
|
2017-02-17 |
2019-12-25 |
Denali Therapeutics Inc |
Anticorps anti-tau et leurs procédés d'utilisation
|
AU2018240029A1
(en)
|
2017-03-22 |
2019-10-17 |
Research Corporation Technologies, Inc. |
Engineered stable CH2 polypeptides
|
WO2018210898A1
(en)
|
2017-05-18 |
2018-11-22 |
F. Hoffmann-La Roche Ag |
Reduction of application-related side reaction of a therapeutic antibody
|
CN111094336A
(zh)
|
2017-08-10 |
2020-05-01 |
戴纳立制药公司 |
使用转铁蛋白受体结合蛋白的基于亲和力的方法
|
US20200277373A1
(en)
|
2017-09-14 |
2020-09-03 |
Denali Therapeutics Inc. |
Anti-trem2 antibodies and methods of use thereof
|
CN111278859A
(zh)
|
2017-10-02 |
2020-06-12 |
戴纳立制药公司 |
包含酶替代疗法酶的融合蛋白
|
WO2019089395A1
(en)
|
2017-11-02 |
2019-05-09 |
Ossianix, Inc. |
Improved tfr-selective binding peptides capable of crossing the blood brain barrier
|
WO2019094608A1
(en)
|
2017-11-08 |
2019-05-16 |
Denali Therapeutics Inc. |
Anti-bace1 antibodies and methods of use thereof
|
CA3088157A1
(en)
|
2018-01-10 |
2019-07-18 |
Denali Therapeutics Inc. |
Transferrin receptor-binding polypeptides and uses thereof
|
US20210046189A1
(en)
|
2018-03-30 |
2021-02-18 |
HANMl PHARM. CO., LTD. |
Long-acting protein conjugates for brain targeting, a preparation method thereof, and a composition comprising the same
|
EP3807322A1
(en)
|
2018-06-18 |
2021-04-21 |
Denali Therapeutics Inc. |
Fusion proteins comprising progranulin
|
AU2019320803A1
(en)
|
2018-08-16 |
2021-03-11 |
Denali Therapeutics Inc. |
Engineered bispecific proteins
|
AU2019326545A1
(en)
|
2018-08-22 |
2021-03-11 |
Denali Therapeutics Inc. |
Anti-HER2 polypeptides and methods of use thereof
|
US20210395381A1
(en)
|
2018-09-14 |
2021-12-23 |
Ossianix, Inc. |
Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
|
WO2020081575A1
(en)
|
2018-10-16 |
2020-04-23 |
Denali Therapeutics Inc. |
Methods for treating and monitoring progranulin-associated disorders
|
EP3887401A2
(en)
|
2018-11-26 |
2021-10-06 |
Denali Therapeutics Inc. |
Methods for treating dysregulated lipid metabolism
|
CA3121927A1
(en)
|
2018-12-10 |
2020-06-18 |
Denali Therapeutics Inc. |
Lysosomal storage disorder biomarkers and methods of use thereof
|
JP2022526799A
(ja)
|
2019-04-03 |
2022-05-26 |
デナリ セラピューティクス インコーポレイテッド |
イズロン酸2-スルファターゼを含むタンパク質分子の製剤
|
AU2020411480B2
(en)
|
2019-12-23 |
2023-12-21 |
Denali Therapeutics Inc. |
Progranulin variants
|
AU2021208482A1
(en)
|
2020-01-13 |
2022-07-21 |
Denali Therapeutics Inc. |
Anti-TREM2 antibodies and methods of use thereof
|
EP4100419A1
(en)
|
2020-02-07 |
2022-12-14 |
Denali Therapeutics Inc. |
Methods for the treatment of hunter syndrome
|
KR20220156526A
(ko)
|
2020-02-19 |
2022-11-25 |
데날리 테라퓨틱스 인크. |
조작된 항-her2 이중특이성 단백질
|
KR20230086703A
(ko)
|
2020-10-14 |
2023-06-15 |
데날리 테라퓨틱스 인크. |
설포글루코사민 설포하이드롤라제 효소를 포함하는 융합 단백질 및 이의 방법
|